https://seekingalpha.com/article/4758211-gossamer-bio-stock-good-speculative-buy-seralutinib-pah-ph-ild [Seeking Alpha]
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS's pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM. Lastly, Gossamer Bio seems to have enough resources to fund both of these trials in 2025. So, I believe its cash runway is sufficient for now. In my view, GOSS is now basically a binary bet on the upcoming Phase 3 data by the end of the year, and for now, it looks reasonably priced relative to its upside potential. KLH49/E+ via Getty Images Gossamer Bio ( NASDAQ: GOSS ) is a clinical-stage biopharmaceutical company that is currently developing a treatment for pulmonary arterial hypertension [PAH] and PH associated with interstitial lung disease [PH-ILD]. Their main drug is Seralutinib, an inhaled tyrosine kinase inhibitor that addresses T
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio: High-Risk Binary Approaches [Seeking Alpha]Seeking Alpha
- Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- How Recent Developments Are Shaping the Gossamer Bio Investment Story [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio to Participate in Upcoming Investor ConferencesBusiness Wire
GOSS
Earnings
- 11/5/25 - Miss
GOSS
Sec Filings
- 11/5/25 - Form 8-K
- 11/5/25 - Form 10-Q
- 10/2/25 - Form 4
- GOSS's page on the SEC website